
PRCT Stock Forecast & Price Target
PRCT Analyst Ratings
Bulls say
PROCEPT BioRobotics Corp has demonstrated consistent growth in utilization, with an average increase of approximately 6.1% in hand pieces per system over the past six quarters, indicating strengthening demand for its products. The company has strategically decided to limit the growth of operating expenses to half of its top-line growth rate, which reflects a dedication to enhancing profitability as it continues to scale operations. Moreover, management's positive outlook is supported by strong performance in capital system placements, with 58 new systems installed in the latest quarter, surpassing previous guidance and suggesting robust market acceptance despite external economic challenges.
Bears say
PROCEPT BioRobotics Corp has experienced a significant decline in its stock price, down approximately 54% year-to-date, despite attempts to surpass its own financial guidance. The company is facing several fundamental challenges, including a potential decline in demand for capital equipment, decreased usage of handpieces by customers, and intensifying competitive pressures, alongside uncertainties related to reimbursement for its Aquablation therapy. Additionally, the consensus forecast for sales in 2026 is anticipated to decrease, reflecting investor concerns regarding utilization rates and inventory levels, further contributing to the negative outlook.
This aggregate rating is based on analysts' research of PROCEPT BioRobotics Corp and is not a guaranteed prediction by Public.com or investment advice.
PRCT Analyst Forecast & Price Prediction
Start investing in PRCT
Order type
Buy in
Order amount
Est. shares
0 shares